{"title":"Capsaicin for osteoarthritis pain.","authors":"Laura L Laslett, Graeme Jones","doi":"10.1007/978-3-0348-0828-6_11","DOIUrl":null,"url":null,"abstract":"<p><strong>Unlabelled: </strong>Capsaicin appears to be effective for osteoarthritis pain but it is uncertain whether the effect has a dose response, is consistent across joints, or changes over time.</p><p><strong>Methods: </strong>Randomized controlled trials of topical capsaicin use in OA were identified from PubMed, EMBASE, and ISI Web of Knowledge. Effect on pain scores, patient global evaluation of treatment effectiveness and application site burning were assessed by standardised mean differences (SMD), using RevMan.</p><p><strong>Results: </strong>Five double-blind randomized controlled trials and one case-crossover trial of topical capsaicin use were identified. Formulations ranged from 0.025 to 0.075%, and trial durations from 4 to 12 weeks. Trials assessed OA of the knee (n = 3), hand (n = 1), and a mix of joints (n = 2). Capsaicin treatment efficacy (vs. placebo) for change in VAS pain score was moderate, at 0.44 (95% CI 0.25-0.62) over 4 weeks of treatment. There was no heterogeneity between studies, indicating no between-study differences, including effect of OA site or treatment concentration. Two studies reported treatment beyond 4 weeks, with divergent results. One study reported an effect size of -9 mm after 12 weeks, and maximal between-group differences at 4 weeks. A second study reported that between-group differences increased over time, up to 20 weeks. Capsaicin was reported as being safe and well-tolerated, with no systemic toxicity. Mild application site burning affected 35-100% of capsaicin-treated patients with a risk ratio of 4.22 (95% CI 3.25-5.48, n = 5 trials); incidence peaked in week 1, with incidence rates declining over time.</p><p><strong>Conclusions: </strong>Topical capsaicin treatment four times daily is moderately effective in reducing pain intensity up to 20 weeks regardless of site of application and dose in patients with at least moderate pain and clinical or radiologically defined OA, and is well tolerated.</p>","PeriodicalId":20603,"journal":{"name":"Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques","volume":"68 ","pages":"277-91"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/978-3-0348-0828-6_11","citationCount":"60","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-3-0348-0828-6_11","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 60
Abstract
Unlabelled: Capsaicin appears to be effective for osteoarthritis pain but it is uncertain whether the effect has a dose response, is consistent across joints, or changes over time.
Methods: Randomized controlled trials of topical capsaicin use in OA were identified from PubMed, EMBASE, and ISI Web of Knowledge. Effect on pain scores, patient global evaluation of treatment effectiveness and application site burning were assessed by standardised mean differences (SMD), using RevMan.
Results: Five double-blind randomized controlled trials and one case-crossover trial of topical capsaicin use were identified. Formulations ranged from 0.025 to 0.075%, and trial durations from 4 to 12 weeks. Trials assessed OA of the knee (n = 3), hand (n = 1), and a mix of joints (n = 2). Capsaicin treatment efficacy (vs. placebo) for change in VAS pain score was moderate, at 0.44 (95% CI 0.25-0.62) over 4 weeks of treatment. There was no heterogeneity between studies, indicating no between-study differences, including effect of OA site or treatment concentration. Two studies reported treatment beyond 4 weeks, with divergent results. One study reported an effect size of -9 mm after 12 weeks, and maximal between-group differences at 4 weeks. A second study reported that between-group differences increased over time, up to 20 weeks. Capsaicin was reported as being safe and well-tolerated, with no systemic toxicity. Mild application site burning affected 35-100% of capsaicin-treated patients with a risk ratio of 4.22 (95% CI 3.25-5.48, n = 5 trials); incidence peaked in week 1, with incidence rates declining over time.
Conclusions: Topical capsaicin treatment four times daily is moderately effective in reducing pain intensity up to 20 weeks regardless of site of application and dose in patients with at least moderate pain and clinical or radiologically defined OA, and is well tolerated.
未标注:辣椒素似乎对骨关节炎疼痛有效,但不确定这种效果是否有剂量反应,是否在关节间一致,或随时间变化。方法:从PubMed, EMBASE和ISI Web of Knowledge中确定OA局部使用辣椒素的随机对照试验。使用RevMan软件,采用标准化平均差(SMD)评估疼痛评分、患者对治疗效果的总体评价和应用部位燃烧的影响。结果:共纳入5项外用辣椒素的双盲随机对照试验和1项病例交叉试验。配方范围为0.025 ~ 0.075%,试验期为4 ~ 12周。试验评估了膝关节(n = 3)、手部(n = 1)和多个关节(n = 2)的OA。在治疗4周后,辣椒素治疗对VAS疼痛评分变化的疗效(与安慰剂相比)为中等,为0.44 (95% CI 0.25-0.62)。研究之间没有异质性,表明研究之间没有差异,包括OA部位或治疗浓度的影响。两项研究报告了超过4周的治疗,结果不同。一项研究报告,12周后效应大小为-9 mm, 4周时组间差异最大。第二项研究报告说,组间差异随着时间的推移而增加,持续到20周。据报道,辣椒素是安全且耐受性良好的,没有全身毒性。轻度应用部位烧伤影响35-100%的辣椒素治疗患者,风险比为4.22 (95% CI 3.25-5.48, n = 5项试验);发病率在第1周达到高峰,随着时间的推移发病率逐渐下降。结论:对于至少有中度疼痛和临床或放射学定义为OA的患者,每日4次局部辣椒素治疗在减轻疼痛强度方面具有中等效果,持续20周,无论应用部位和剂量如何,并且耐受性良好。